A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays | Zendy

Qiang Wang | Zendy; Qin Du | Zendy; Bin Guo | Zendy; Daiyong Mu | Zendy; Xiaolan Lu | Zendy; Qiang Ma | Zendy; Yangliu Guo | Zendy; Fang Li | Zendy; Bing Zhang | Zendy; Guoyuan Zhang | Zendy; Xiaolan Guo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays

Author(s) -

Qiang Wang,

Qin Du,

Bin Guo,

Daiyong Mu,

Xiaolan Lu,

Qiang Ma,

Yangliu Guo,

Fang Li,

Bing Zhang,

Guoyuan Zhang,

Xiaolan Guo

Publication year - 2020

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.00375-20

Subject(s) - mycoplasma pneumoniae , virology , medicine , immunoglobulin m , virus , antibody , immunology , coronavirus , pneumonia , microbiology and biotechnology , immunoglobulin g , biology , covid-19 , disease , infectious disease (medical specialty)

We set out to investigate the interference factors that led to false-positive novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM detection results using gold immunochromatography assay (GICA) and enzyme-linked immunosorbent assay (ELISA) and the corresponding solutions. GICA and ELISA were used to detect SARS-CoV-2 IgM in 86 serum samples, including 5 influenza A virus (Flu A) IgM-positive sera, 5 influenza B virus (Flu B) IgM-positive sera, 5 Mycoplasma pneumoniae IgM-positive sera, 5 Legionella pneumophila IgM-positive sera, 6 sera of HIV infection patients, 36 rheumatoid factor IgM (RF-IgM)-positive sera, 5 sera from hypertensive patients, 5 sera from diabetes mellitus patients, and 14 sera from novel coronavirus infection disease 19 (COVID-19) patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research